Emery, Paul http://orcid.org/0000-0002-7429-8482
Tanaka, Yoshiya
Bykerk, Vivian P.
Huizinga, Thomas W. J.
Citera, Gustavo
Bingham, Clifton O. 3rd
Banerjee, Subhashis
Soule, Benjamin P.
Nys, Marleen
Connolly, Sean E.
Lozenski, Karissa L.
Zhuo, Joe
Wong, Robert
Huang, Kuan-Hsiang Gary
Fleischmann, Roy
Clinical trials referenced in this document:
Documents that mention this clinical trial
FRI0090 MAINTENANCE OF CLINICAL RESPONSE WITH ABATACEPT IN COMBINATION WITH MTX IN INDIVIDUAL PATIENTS WITH EARLY RA WHO ARE MTX-NAÏVE AND ANTI-CITRULLINATED PROTEIN ANTIBODY (ACPA)+: RESULTS FROM THE INDUCTION PERIOD OF AVERT-2, A RANDOMISED PHASE IIIB STUDY
https://doi.org/10.1136/annrheumdis-2020-eular.2367
THU0095 IMPACT OF BASELINE EROSION SCORE ON RESPONSE TO TREATMENT AND FUTURE RADIOLOGICAL DAMAGE IN AVERT-2, A RANDOMISED PHASE IIIB STUDY OF ABATACEPT IN MTX-NAÏVE, ANTI-CITRULLINATED PROTEIN ANTIBODY–POSITIVE (ACPA+) PATIENTS WITH EARLY RA
https://doi.org/10.1136/annrheumdis-2020-eular.1238
SAT0104 MAINTENANCE OF SDAI REMISSION AND PATIENT-REPORTED OUTCOMES (PROS) FOLLOWING DOSE DE-ESCALATION OF ABATACEPT IN MTX-NAÏVE, ANTI-CITRULLINATED PROTEIN ANTIBODY (ACPA)+ PATIENTS WITH EARLY RA: RESULTS FROM AVERT-2, A RANDOMISED PHASE IIIB STUDY
https://doi.org/10.1136/annrheumdis-2020-eular.1429
FRI0038 THE RELATIONSHIP BETWEEN ABATACEPT EXPOSURE AND EFFICACY MEASURES IN EARLY MTX-NAIVE ANTI-CITRULLINATED PROTEIN ANTIBODY-POSITIVE PATIENTS WITH RA DURING THE DE-ESCALATION PERIOD OF A PHASE IIIB STUDY
https://doi.org/10.1136/annrheumdis-2020-eular.6017
POS0474 SUBSTANTIAL IMPACT OF AUTOANTIBODY ENRICHMENT ON OUTCOMES IN EARLY RHEUMATOID ARTHRITIS TREATED WITH ABATACEPT: DATA FROM A LARGE POOLED ANALYSIS OF 4 RCTS
https://doi.org/10.1136/annrheumdis-2021-eular.2513
Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis
https://doi.org/10.1007/s40744-022-00519-9
Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2022-002683
POS0611 BASELINE IL-10 LEVELS AS A PREDICTIVE BIOMARKER FOR ACHIEVING CLINICAL RESPONSE WITH ABATACEPT IN ACPA+ PATIENTS WITH EARLY RA
https://doi.org/10.1136/annrheumdis-2024-eular.118
Funding for this research was provided by:
Bristol Myers Squibb
Article History
Received: 8 March 2022
Accepted: 2 December 2022
First Online: 3 March 2023